Miller DM - Search Results

1

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.

Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Telang S, et al. Among authors: miller dm. BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515. BMC Cancer. 2011. PMID: 22165955 Free PMC article. Clinical Trial.

2

Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.

Natarajan N, Telang S, Miller D, Chesney J. Natarajan N, et al. Drugs. 2011 Jul 9;71(10):1233-50. doi: 10.2165/11591380-000000000-00000. Drugs. 2011. PMID: 21770473 Review.

3

Transient T cell depletion causes regression of melanoma metastases.

Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J. Rasku MA, et al. Among authors: miller dm. J Transl Med. 2008 Mar 11;6:12. doi: 10.1186/1479-5876-6-12. J Transl Med. 2008. PMID: 18334033 Free PMC article. Clinical Trial.

4

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J. Clem BF, et al. Among authors: miller dm. Mol Cancer Ther. 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14. Mol Cancer Ther. 2013. PMID: 23674815 Free PMC article.

5

5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma.

Gill A, Gosain R, Gragg H, Bycroft R, Rai SN, Pan J, Chesney JA, Miller DM. Gill A, et al. Among authors: miller dm. Am J Med Sci. 2019 Jan;357(1):43-48. doi: 10.1016/j.amjms.2018.10.009. Epub 2018 Oct 25. Am J Med Sci. 2019. PMID: 30611319

6

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.

Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, Miller DM. Laber DA, et al. Among authors: miller dm. J Cancer Res Clin Oncol. 2006 Sep;132(9):611-6. doi: 10.1007/s00432-006-0114-8. Epub 2006 Jun 2. J Cancer Res Clin Oncol. 2006. PMID: 16741726 Clinical Trial.

7

Obtaining routine blood cultures during interleukin-2-containing therapy is unnecessary.

Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Jaglal MV, et al. Among authors: miller dm. Am J Clin Oncol. 2009 Aug;32(4):429-31. doi: 10.1097/COC.0b013e31819142c7. Am J Clin Oncol. 2009. PMID: 19451801

8

Digitalis, a targeted therapy for cancer?

Khan MI, Chesney JA, Laber DA, Miller DM. Khan MI, et al. Among authors: miller dm. Am J Med Sci. 2009 May;337(5):355-9. doi: 10.1097/MAJ.0b013e3181942f57. Am J Med Sci. 2009. PMID: 19440057 Review.

9

Melanoma of unknown primary: favorable survival persists in the immunotherapy era.

Maharaj S, Jain N, Al Bawaliz A, Miller D, Chesney J. Maharaj S, et al. Int J Dermatol. 2023 Apr;62(4):e236-e238. doi: 10.1111/ijd.16419. Epub 2022 Aug 28. Int J Dermatol. 2023. PMID: 36030543 No abstract available.

10

Hypoxia induces differential translation of enolase/MBP-1.

Sedoris KC, Thomas SD, Miller DM. Sedoris KC, et al. Among authors: miller dm. BMC Cancer. 2010 Apr 22;10:157. doi: 10.1186/1471-2407-10-157. BMC Cancer. 2010. PMID: 20412594 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

733 results

Search Page

Filters